Reading the tape
NASDAQ: NAGE
Niagen Bioscience Inc
Healthcare · Biotechnology
Market Cap
$385.99M
52w High
$14.69
52w Low
$4.16
P/E
21.90
Volume
877.47K
Outstanding Shares
80.08M
Price vs Fundamentals
Why The Stock Is Moving
Likely multiple compressionModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -43.14%Revenue (TTM): 29.95%FCF (TTM): 10.14%P/FCF: 30th pct
What changed
The stock fell 43.14% over the last year. Revenue grew 29.95% over the trailing twelve months. Operating margin moved from 7.76% to 11.05%. Free cash flow grew 10.14% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price, and the shares now sit around the 30th percentile of their historical P/FCF range. That looks more like a rerating of the multiple than a collapse in the business.
What would invalidate this read
This read changes if operating margin (currently 11.05%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Company profile
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging.
CEORobert N. Fried
SectorHealthcare
IndustryBiotechnology
Employees104
IPO dateJun 24, 2015
Valuation
Forward P/E—
EV/EBITDA28.05
Enterprise value$441.6M
Stock splits
Apr 13, 2016↓ Reverse
Every 3 shares became 1
Profitability & growth
Revenue growth16.19%
Gross margin64.28%▲3.95%vs FY2024
Operating margin11.05%▲42.39%vs FY2024
ROE22.71%▲22.44%vs FY2024
Analyst consensus
RatingBuy
Target price$10.00▲107.47%
5
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 6, 2026
Q2 FY26 · EPS est $0.06 · Revenue est $30.95M
View